GRANZER REGULATORY CONSULTING & SERVICES
Desconocido
XVR011 Phase 2: ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS...
GRANZER HEINZ ULRICH
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-CORONA-01
XVR011, ExeVir's clinical lead candidate has emerged from scientific research from labs of highly regarded virologist Xavier Saelens and bio...
2021-11-15 - 2022-11-30 | Financiado
2021-11-15 - 2022-11-30 | Financiado
IMMUNISA: A Next Generation Immunotherapy for Human Papilloma Virus induced Cervical Cancer
GRANZER HEINZ ULRICH
participó en un
H2020:
H2020-SC1-2016-2017
Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16). Prophylactic HPV vaccination is not the standa...
2017-11-21 - 2022-11-30 | Financiado
2017-11-21 - 2022-11-30 | Financiado
* No se disponen de datos de la empresa actual.